Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00093132
Status:
TERMINATED
Last Update Posted:
2012-08-17
First Post:
2004-10-01
Brief Title:
Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy
Sponsor:
Agennix
Organization:
Agennix
Study Overview
Official Title:
A Phase 12 Study With Satraplatin and Simultaneous Radiation in Locally Advanced Non-Small Cell Lung Cancer
Status:
TERMINATED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsor decided to discontinue study drug development
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
PURPOSE This trial is designed to compare the combination of the investigational oral cytotoxic drug satraplatin and radiation therapy for patients with locally advanced Non-Small Cell Lung Cancer NSCLC with no prior chemotherapy or radiation therapy treatment Please refer to the Eligibility Criteria below for key inclusion and exclusion criteria
WHAT IS SATRAPLATIN Satraplatin is an oral investigational anticancer drug that is a member of the platinum-based class of chemotherapy drugs Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies Unlike the currently marketed platinum-based drugs satraplatin can be given orally
RATIONALE Intravenously administered platinum-based drugs are currently used in combination with radiation therapy in the treatment of patients with locally advanced NSCLC The purpose of this Phase I trial is to determine a tolerable dose and schedule for the oral platinum drug satraplatin when given to NSCLC patients throughout the course of their radiotherapy treatment
WHAT IS SATRAPLATIN Satraplatin is an oral investigational anticancer drug that is a member of the platinum-based class of chemotherapy drugs Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies Unlike the currently marketed platinum-based drugs satraplatin can be given orally
RATIONALE Intravenously administered platinum-based drugs are currently used in combination with radiation therapy in the treatment of patients with locally advanced NSCLC The purpose of this Phase I trial is to determine a tolerable dose and schedule for the oral platinum drug satraplatin when given to NSCLC patients throughout the course of their radiotherapy treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None